Pipeline

Viatonix focuses on the development of immuno-oncology therapeutics for the treatment of cancer and other malignant diseases.

Our pipeline comprises several drug candidates that have the potential for broad application in the treatment of oncological and malignant hematological indications.

Asunercept, a CD95 ligand inhibitor, is currently in clinical development for the treatment of glioblastoma and myelodysplastic syndromes. Preclinical studies in a variety of tumor indications highlight the potential of asunercept in other solid tumors and malignant hematological diseases.

Viatonix has also developed the proprietary HERA-ligand technology platform for the construction of novel TNFSF receptor agonists for     the treatment of cancer. Preclinical experiments have shown that  these agonists effectively stimulate the immune system and exhibit potent anti-tumor efficacy in different model systems, thus making them promising candidates for the treatment of solid tumors.

The excellent anti-tumor efficacy of Viatonix’ TRAIL receptor agonists has been demonstrated in a large number of preclinical studies. Viatonix has entered into a licensing agreement with AbbVie

 in 2014. In March 2017, AbbVie initiated a clinical phase I study with ABBV-621 in patients suffering from solid tumors, non-Hodgkin's lymphoma (NHL) or acute myeloid leukemia (AML).


Asunercept – Overview
Asunercept as a Therapeutic for Solid Tumors
Asunercept – Overview
Viatonix’ lead drug candidate asunercept (APG101) is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody. Asunercept is being developed for the treatment of solid tumors and malignant hematological diseases and has been evaluated in the treatment of glioblastoma and myelodysplastic syndromes (MDS).

The excellent tolerability of was shown in a double-blind, placebo-controlled phase I trial in healthy volunteers. Even the highest dose of 20 mg/kg body weight was very well tolerated and no anti-drug antibodies against were detected.
Asunercept as a Therapeutic for Solid Tumors
Asunercept inhibits the CD95 ligand which plays an important role in the progression of solid tumors. Depending on the target cell – immune cell or tumor cell – the interaction between the CD95 ligand and the CD95 receptor induces either apoptotic cell death or invasive growth of cells. Consequently, asunercept has a dual mechanism of action.